CN114642772A - Tragacanth/chitosan/hybrid nano apatite ternary composite porous material and preparation method thereof - Google Patents
Tragacanth/chitosan/hybrid nano apatite ternary composite porous material and preparation method thereof Download PDFInfo
- Publication number
- CN114642772A CN114642772A CN202210385270.3A CN202210385270A CN114642772A CN 114642772 A CN114642772 A CN 114642772A CN 202210385270 A CN202210385270 A CN 202210385270A CN 114642772 A CN114642772 A CN 114642772A
- Authority
- CN
- China
- Prior art keywords
- porous material
- chitosan
- tragacanth
- apatite
- hybrid nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a tragacanth/chitosan/hybrid nano apatite ternary composite porous material and a preparation method thereof, wherein the porous material is prepared by ultrasonically stirring and uniformly mixing three compounds of tragacanth, chitosan and hybrid nano apatite in an aqueous solution, adding a small amount of glacial acetic acid to obtain a composite gel, placing the composite gel in a culture dish for precooling, freeze-drying, finally soaking and washing the composite gel in a NaOH solution to be neutral, and drying. The polyanionic tragacanth and the cationic chitosan acid solution have strong ionic crosslinking, so that the mechanical property and the degradation property of the porous material are greatly improved, and the added hybrid nano apatite contains a small amount of diphosphate, so that the osteogenic activity is better. The novel porous material is simple in preparation method, the sources of the used raw materials are rich, the mechanical property, the degradation property and the osteogenic activity of the novel porous material can be regulated and controlled through the change of the content of each component of the porous material, and the novel porous material is expected to obtain a bone tissue engineering scaffold material with excellent performance.
Description
Technical Field
The invention relates to a tragacanth/chitosan/hybrid nano apatite ternary composite porous material and a preparation method thereof, belonging to the field of biomedical materials.
Background
The bone tissue engineering scaffold material is a key element for bone tissue engineering research, and an ideal bone tissue engineering scaffold has good osteoconductivity, high porosity, excellent mechanical strength and a proper degradation rate. The bone tissue engineering scaffold comprises a degradable polymer, bioactive ceramics and an inorganic/organic composite scaffold, wherein the inorganic/organic composite scaffold combines the advantages of the polymer and the bioactive ceramics, so that the nano-hydroxyapatite/chitosan (n-HA/CS) composite porous material becomes a research hotspot of the bone tissue engineering scaffold. However, n-HA/CS HAs the problems of insufficient mechanical property and osteogenic activity in application. In the previous research, the applicant introduced carboxylated bamboo fibers into a polycationic chitosan system by using the electrostatic self-assembly principle of high polymers to prepare a porous ternary composite material with higher strength. However, the modification steps of the carboxylated bamboo fiber are complicated, and the osteogenic activity of the nano-hydroxyapatite itself is to be improved, so that other polyanionic high polymers and a porous material compounded by the nano-apatite and the chitosan with high osteogenic activity are to be explored.
Tragacanth, a natural polyanionic polysaccharide, has a backbone composed of partially methoxylated D-galacturonic acid units linked by α -1,4 linkages and side chains composed of many different polysaccharides. The tragacanth is a colloidal secretion from plants of the genus Dolabra, has good biocompatibility, degradability, non-toxicity and acid resistance, has been used in the fields of food additives, thickeners, stabilizers, emulsifiers, hydrogels and pharmaceuticals, and has also been widely used in the pharmaceutical fields of drug carriers, wound healing dressings, skin regeneration and the like. However, no report is found on whether the tragacanth gum can be prepared into a porous material for a bone tissue engineering scaffold by the ionic crosslinking effect with chitosan.
In addition, in order to improve the osteogenic activity of the nano hydroxyapatite, various trace elements such as strontium, silicon and the like are doped into the n-HA, so that the biological performance of the nano hydroxyapatite can be improved, but the effective doping amount is difficult to control. The loaded bone growth factor is beneficial to promoting the growth of bone tissues, but the growth factor has short half-life period, is easy to rapidly degrade in vivo and dilute by body fluid, is easy to cause local toxicity and angiomatous lesion when loaded in large dose, and is expensive. The diphosphonate is used for treating osteoporosis, but can be introduced into the preparation process of n-HA to prepare hybrid nano apatite with high osteogenic activity, and is used for preparing a porous composite material with a polymer to be used for a bone tissue engineering scaffold, and the report is not shown, so that the diphosphonate is worthy of being deeply explored.
Disclosure of Invention
In view of the above situation, the present invention aims to provide a tragacanth/chitosan/hybrid nano apatite ternary composite porous material and a preparation method thereof. The composite porous material prepared by the invention has higher mechanical property, degradation property and biocompatibility, is a novel degradable porous material with high strength and high osteogenic activity, and can meet the basic requirements of the performance of a scaffold material for bone tissue engineering.
The invention adopts the following technical scheme: tragacanth gum is commercially available with a viscosity of greater than 1000; the hybrid nano apatite is characterized in that the nano apatite contains a small amount of bisphosphates such as zoledronate, alendronate and pamidronate; the chitosan has a deacetylation degree of more than 90% and a viscosity-average molecular weight of 20-40 ten thousand.
The invention relates to hybrid nano apatite, which is characterized in that bisphosphate is dissolved in water and slowly dripped into a calcium nitrate solution to react for 1 hour, a sodium phosphate solution is slowly dripped into the mixed solution, the Ca/P molar ratio is kept to be 1.67, the adding content of the bisphosphate is 0.1-1% of the mass of the nano apatite, the pH value is adjusted to be more than 10 by 1 mol/L sodium hydroxide, the mixture is heated and stirred for 4 hours at 70 ℃, and is aged for 48 hours, washed to be neutral by deionized water, dried and ground into powder.
The invention provides a tragacanth/chitosan/hybrid nano apatite ternary composite porous material, which is realized by the following technical scheme and is characterized by adopting the following process steps:
ultrasonically dispersing a certain amount of hybrid nano apatite slurry, slowly adding a certain amount of mixed powder of chitosan and tragacanth, mechanically stirring at a high speed for 2-4 hours, and adding glacial acetic acid with the concentration of 2-4% to obtain compound gel; freezing at-20 deg.C for 12 hr, and freeze drying; and soaking the dried porous material in a 5-10% NaOH solution for 30 minutes, then washing the porous material to be neutral by using deionized water, and drying the porous material in vacuum at 40 ℃ to constant weight.
Compared with the existing porous material, the porous material of the invention has the advantages that:
(1) the chitosan and the tragacanth used in the invention are natural degradable polymers with good biocompatibility, and the raw materials have wide sources and low price; the tragacanth tape has negative electricity and can generate ion crosslinking with a chitosan solution with positive electricity, so that the mechanical property of the composite porous material is improved, the degradation performance of the composite porous material is greatly slowed down, and the composite porous material can provide a longer-time supporting effect; more importantly, both chitosan and tragacanth have natural antibacterial property, and can continuously and slowly prevent infection; in addition, the added hybrid nano apatite containing diphosphonate has better bone conductivity than the traditional nano hydroxyapatite and can be released slowly and continuously. In conclusion, the selected tragacanth and the hybrid nano apatite are beneficial to improving the mechanical property, the degradation property and the bone conductivity of the n-HA/CS composite porous material, and can also improve the antibacterial property.
(2) The tragacanth/chitosan/hybrid nano apatite ternary composite porous material provided by the invention has the advantages of simple and feasible preparation process, low production cost, greenness and environmental protection, and is suitable for mass production; the mechanical property, the degradation property, the bone conductivity and the antibacterial property of the porous composite material can be regulated and controlled by adjusting the content of each component, and meanwhile, other medicines can be added to obtain a bone tissue engineering scaffold material with better performance.
Drawings
FIG. 1 is SEM photograph of a tragacanth/chitosan/hybrid nano apatite ternary composite porous material and a simulated body fluid soaked in the ternary composite porous material for 8 weeks.
Detailed Description
Example 1: weighing 4.0 g of chitosan (the deacetylation degree is 90%, the molecular weight is 20 ten thousand), adding 100 ml of deionized water, adding 2.0 g of tragacanth, simultaneously ultrasonically dispersing 2.0 g of hybridized nano apatite containing 0.5 wt% of zoledronate in 100 ml of deionized water, dropwise adding into the tragacanth/chitosan mixed solution, continuously carrying out ultrasonic magnetic stirring for 3 hours, and adding 5 ml of glacial acetic acid to obtain the tragacanth/chitosan/hybridized nano apatite ternary composite gel. Freezing in a refrigerator at-20 deg.C for 12 hr, and freeze drying to constant weight with a freeze dryer. And finally, soaking the mixture in 8 percent NaOH solution for 30 minutes, washing the mixture to be neutral, and drying the mixture. Cutting the material into blocks of 10 mm multiplied by 10 mm, and measuring that the compression strength is about 0.8 MPa, the porosity is 81 percent, and the average pore diameter is 200 um; the in vitro simulated body fluid is soaked by 8 w, a great amount of bone-like apatite is deposited on the surface, and the compressive strength can still maintain about 0.3 MPa.
Example 2: weighing 4.0 g of chitosan (the deacetylation degree is 95%, the molecular weight is 30 ten thousand), adding 100 ml of deionized water, adding 1.0 g of tragacanth, simultaneously ultrasonically dispersing 2.5 g of hybridized nano apatite containing 0.3 wt% of alendronate in 100 ml of deionized water, dropwise adding into the tragacanth/chitosan mixed solution, continuously carrying out ultrasonic magnetic stirring for 3 hours, and adding 6 ml of glacial acetic acid to obtain the tragacanth/chitosan/hybridized nano apatite ternary composite gel. Freezing in a refrigerator at-20 deg.C for 12 hr, and freeze drying to constant weight with a freeze dryer. Then soaking the mixture in 10% NaOH solution for 30 minutes, washing the mixture to be neutral, and drying the mixture to obtain the finished product. Cutting the material into blocks of 10 mm multiplied by 10 mm, and measuring that the compression strength is about 1.0 MPa, the porosity is 79 percent, and the average pore diameter is 220 um; the in vitro simulated body fluid is soaked by 8 w, a great amount of bone-like apatite is deposited on the surface, and the compressive strength can still maintain about 0.4 MPa.
Example 3: weighing 4.5 g of chitosan (the deacetylation degree is 95%, the molecular weight is 20 ten thousand), adding 100 ml of deionized water, adding 1.5 g of tragacanth, simultaneously ultrasonically dispersing 4.0 g of hybridized nano apatite containing 1.0 wt% of alendronate in 100 ml of deionized water, dropwise adding into the tragacanth/chitosan mixed solution, continuously carrying out ultrasonic magnetic stirring for 4 hours, and adding 8 ml of glacial acetic acid to obtain the tragacanth/chitosan/hybridized nano apatite ternary composite gel. Freezing in a refrigerator at-20 deg.C for 12 hr, and freeze drying to constant weight with a freeze dryer. Then soaking the mixture in 10% NaOH solution for 30 minutes, washing the mixture to be neutral, and drying the mixture. Cutting the material into blocks of 10 mm multiplied by 10 mm, and measuring that the compression strength is about 0.6 MPa, the porosity is 78 percent and the average pore diameter is 150 um; the in vitro simulated body fluid is soaked in 8 w, a large amount of bone-like apatite is deposited on the surface, and the compressive strength can still maintain about 0.1 MPa.
Comparative example 1: weighing 4.0 g of chitosan (the deacetylation degree is 95%, the molecular weight is 30 ten thousand), adding 200 ml of deionized water, adding 6 ml of glacial acetic acid, stirring until the chitosan is dissolved, dropwise adding a dispersion liquid in which 2.0 g of nano-hydroxyapatite is ultrasonically dispersed in 100 ml of water into the chitosan solution, and continuously performing ultrasonic magnetic stirring for 2 hours to obtain the nano-hydroxyapatite/chitosan binary composite gel. Freezing in a refrigerator at-20 deg.C for 48 hr, and freeze drying to constant weight with a freeze dryer. Then soaking the mixture in 10% NaOH solution for 30 minutes, washing the mixture to be neutral, and drying the mixture. Cutting the material into blocks of 10 mm multiplied by 10 mm, and measuring that the compression strength is about 0.4 MPa, the porosity is 73 percent, and the average pore diameter is 150 um; the porous material is degraded into powder after being soaked in simulated body fluid in vitro for 8 w.
Comparative example 2: weighing 4.5 g of chitosan (the deacetylation degree is 95%, the molecular weight is 20 ten thousand), adding 100 ml of deionized water, adding 1.5 g of tragacanth, simultaneously dropwise adding a dispersion liquid in which 2.0 g of nano-hydroxyapatite is ultrasonically dispersed in 300 ml of water into the tragacanth/chitosan mixed solution, continuing ultrasonic magnetic stirring for 4 hours, and adding 8 ml of glacial acetic acid to obtain the tragacanth/chitosan/nano-apatite ternary composite gel. Freezing in a refrigerator at-20 deg.C for 12 hr, and freeze drying to constant weight with a freeze dryer. Then soaking the mixture in 10% NaOH solution for 30 minutes, washing the mixture to be neutral, and drying the mixture. Cutting the material into blocks of 10 mm multiplied by 10 mm, and measuring that the compression strength is about 0.7 MPa, the porosity is 80 percent and the average aperture is 150 um; the in vitro simulated body fluid is soaked by 8 w, a small amount of bone-like apatite is deposited on the surface, and the compressive strength can still maintain about 0.2 MPa.
The test conditions of the compressive strength are as follows: the compression property was measured by a universal material testing machine (SANSCMT 4503, SANS, Shenzhen, China) for a 10 mm × 10 mm block material cut out to a compression deformation of 40%. The test temperature was 20 ℃ 2 ℃ and the loading speed was 1 mm/min. Five replicates were tested per group and the results averaged.
Determination of porosity: adding a proper amount of absolute ethyl alcohol into the vector cylinder, and recording the dry weight of the cut 10 mm multiplied by 10 mm block-shaped material as m1Adding into absolute ethyl alcohol, weighing ethyl alcohol and marking the initial volume of the sample as V1. Soaking at room temperature for 1 week, taking out the material, and weighing the material with wet weight of m2Volume of remaining ethanol is V2. Then porosity θ = [ (m)2-m1)/ρ]/(V1-V2). Three replicates of each sample were measured and averaged.
Claims (4)
1. A tragacanth/chitosan/hybrid nano apatite ternary composite porous material is characterized in that tragacanth, chitosan and hybrid nano apatite are ultrasonically stirred and uniformly mixed in an aqueous solution, a small amount of glacial acetic acid is added to obtain a composite gel, the composite gel is placed in a culture dish for precooling and freeze drying, and finally, the composite gel is soaked in a NaOH solution, washed to be neutral and dried.
2. The tragacanth/chitosan/hybrid nano-apatite ternary composite porous material as claimed in claim 1, wherein the mass ratio of the tragacanth to the chitosan is 1/5-5/1, and the mass ratio of the hybrid nano-apatite in the composite material is 10% -60%.
3. The hybrid nano apatite as claimed in claim 2, which is characterized by containing 0.1-1% bisphosphate
Nano apatite of salt.
4. The bisphosphate of hybrid nanoapatite as claimed in claim 3, which is characterized by referring to zoledronate,
Alendronate, pamidronate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210385270.3A CN114642772B (en) | 2022-04-13 | 2022-04-13 | Tragacanth/chitosan/hybrid nano apatite ternary composite porous material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210385270.3A CN114642772B (en) | 2022-04-13 | 2022-04-13 | Tragacanth/chitosan/hybrid nano apatite ternary composite porous material and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114642772A true CN114642772A (en) | 2022-06-21 |
| CN114642772B CN114642772B (en) | 2023-01-06 |
Family
ID=81997202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210385270.3A Active CN114642772B (en) | 2022-04-13 | 2022-04-13 | Tragacanth/chitosan/hybrid nano apatite ternary composite porous material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114642772B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110063939A (en) * | 2019-06-11 | 2019-07-30 | 邢更彦 | Shock wave mediates the hollow hydroxyapatite of release to carry medicine particle and preparation method thereof |
-
2022
- 2022-04-13 CN CN202210385270.3A patent/CN114642772B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110063939A (en) * | 2019-06-11 | 2019-07-30 | 邢更彦 | Shock wave mediates the hollow hydroxyapatite of release to carry medicine particle and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| SHADPOUR MALLAKPOUR，等: "Hydroxyapatite mineralization of chitosan-tragacanth blend/ZnO/Ag nanocomposite films with enhanced antibacterial activity", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114642772B (en) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qi et al. | Investigation of Salecan/poly (vinyl alcohol) hydrogels prepared by freeze/thaw method | |
| EP1901786B1 (en) | Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process | |
| WO2015085633A1 (en) | Hydrogel based on γ-polyglutamic acid and ε-polylysine crosslinked polymer, and preparation method therefor | |
| CN1182753A (en) | Solvent dried polysaccharide sponges | |
| WO2008103017A1 (en) | Biodegradable porous composite and hybrid composite of biopolymers and bioceramics | |
| Kim et al. | Injectable hydrogels derived from phosphorylated alginic acid calcium complexes | |
| Liu et al. | Biomedical applications of bacterial cellulose based composite hydrogels | |
| CN110152055A (en) | The functional drug that alginic acid amination derivative/bacteria cellulose nanocomposite gel is constructed is sustained medical dressing | |
| CN113004543A (en) | Nano lignin/polyvinyl alcohol composite medical hydrogel and preparation method thereof | |
| CN114404646B (en) | CM-beta-CD supported tannic acid polyacrylamide type double-network antibacterial hydrogel | |
| CN110613864B (en) | Modified bamboo fiber reinforced chitosan-based porous material and preparation method thereof | |
| CN103007342A (en) | Biodegradable and medical tricalcium phosphate/gamma-polyglutamic acid composite and preparation method thereof | |
| KR100889593B1 (en) | Hybrid Composite of Biopolymers and Bioceramics, and Method for Preparing the Same | |
| CN113209382B (en) | Three-dimensional reticular chitosan slow-release coating and preparation method thereof | |
| CN110613863B (en) | Porous scaffold material for promoting vascularization based on silicon-doped hydroxyapatite and preparation method and application thereof | |
| CN114642772B (en) | Tragacanth/chitosan/hybrid nano apatite ternary composite porous material and preparation method thereof | |
| CN108478874B (en) | Preparation method of hydroxyethyl chitosan nano composite bone scaffold material | |
| CZ307615B6 (en) | An antimicrobial composition comprising a polysaccharide, a stabilizer and a triiodide, a method for its preparation and use | |
| WO2020249143A1 (en) | Means for use in preparation of hydrogel based on hydroxyphenyl derivative of hyaluronan, method of hydrogel preparation and use thereof | |
| CN112704765A (en) | Chitosan-graphene oxide composite gel and preparation method thereof | |
| KR100523701B1 (en) | The Method of Preparation of Porous Gel Sponge Using Hyaluronan and Anhydrides | |
| Mehrabi et al. | Evaluation of inherent properties of the carboxymethyl cellulose (CMC) for potential application in tissue engineering focusing on bone regeneration | |
| Lu et al. | Rapidly in situ forming biodegradable hydrogels by combining alginate and hydroxyapatite nanocrystal | |
| CN117815453A (en) | Preparation method of sisal fiber reinforced chitosan-based antibacterial porous material with high osteogenesis activity | |
| RU2714671C1 (en) | Three-dimensional porous composite material and a method for production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |